VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Thursday, January 8, 2026

Stock Comparison

ASSA ABLOY AB vs Eli Lilly and Company

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

ASSA ABLOY AB

ASSA-B · Nasdaq Stockholm

Market cap (USD)$392.9B
Gross margin (TTM)42.3%
Operating margin (TTM)15.2%
Net margin (TTM)9.6%
SectorIndustrials
IndustrySecurity & Protection Services
CountrySE
Data as of2026-01-02
Moat score
76/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into ASSA ABLOY AB's moat claims, evidence, and risks.

View ASSA-B analysis

Eli Lilly and Company

LLY · New York Stock Exchange

Market cap (USD)$935.6B
Gross margin (TTM)83%
Operating margin (TTM)43.9%
Net margin (TTM)31%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
Data as of2026-01-05
Moat score
66/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Eli Lilly and Company's moat claims, evidence, and risks.

View LLY analysis

Comparison highlights

  • Moat score gap: ASSA ABLOY AB leads (76 / 100 vs 66 / 100 for Eli Lilly and Company).
  • Segment focus: ASSA ABLOY AB has 5 segments (32.9% in Entrance Systems); Eli Lilly and Company has 5 segments (65.5% in Cardiometabolic Health).
  • Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
  • Moat breadth: ASSA ABLOY AB has 4 moat types across 2 domains; Eli Lilly and Company has 5 across 2.

Primary market context

ASSA ABLOY AB

Entrance Systems

Market

Entrance automation and industrial door solutions (pedestrian automatic doors, industrial doors, loading dock equipment, service/maintenance)

Geography

Global

Customer

Commercial/industrial facilities via distributors, installers and service channels

Role

OEM + service/maintenance provider

Revenue share

32.9%

Eli Lilly and Company

Cardiometabolic Health

Market

Branded cardiometabolic pharmaceuticals (type 2 diabetes, obesity, and related metabolic/cardiovascular conditions; especially incretin therapies)

Geography

Global

Customer

Patients via prescribers; payers/PBMs; wholesaler & pharmacy channels

Role

Drug developer, manufacturer, and marketer

Revenue share

65.5%

Side-by-side metrics

ASSA ABLOY AB
Eli Lilly and Company
Ticker / Exchange
ASSA-B - Nasdaq Stockholm
LLY - New York Stock Exchange
Market cap (USD)
$392.9B
$935.6B
Gross margin (TTM)
42.3%
83%
Operating margin (TTM)
15.2%
43.9%
Net margin (TTM)
9.6%
31%
Sector
Industrials
Healthcare
Industry
Security & Protection Services
Drug Manufacturers - General
HQ country
SE
US
Primary segment
Entrance Systems
Cardiometabolic Health
Market structure
Oligopoly
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Strong
Moat score
76 / 100
66 / 100
Moat domains
Demand, Supply
Legal, Supply
Last update
2026-01-02
2026-01-05

Moat coverage

Shared moat types

No overlap yet.

ASSA ABLOY AB strengths

Installed Base ConsumablesService Field NetworkBrand TrustSwitching Costs General

Eli Lilly and Company strengths

IP Choke PointCapacity MoatLearning Curve YieldOperational ExcellenceCompliance Advantage

Segment mix

ASSA ABLOY AB segments

Full profile >

Opening Solutions EMEIA

Oligopoly

16.3%

Opening Solutions Americas

Oligopoly

29.4%

Opening Solutions Asia Pacific

Competitive

5.5%

Global Technologies

Oligopoly

16%

Entrance Systems

Oligopoly

32.9%

Eli Lilly and Company segments

Full profile >

Cardiometabolic Health

Oligopoly

65.5%

Oncology

Competitive

19.4%

Immunology

Competitive

9.8%

Neuroscience

Competitive

3.3%

Other

Competitive

2%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.